Amberstone Biosciences Inc
October 17, 2023
Company Description: Amberstone Biosciences is developing a new class of paradigm-shifting, Tumor Microenvironment Activated ThErapeutic (“T-MATE”) antibodies and cytokines that can offer significantly improved safety and efficacy profile. The company's passionate team has also developed a robust platform capability of T-MATE discovery that integrates cutting-edge technologies (single-cell functional screening, direct evolution, CADD and AI/ML), to drive continued innovations. We invite serious partners & investors to work with us and grow with us to make a difference for cancer patients.
CEO/Top Company Official
Lead Product in Development
Conditionally activated TROP-2 targeting T-cell-engager T-MATE molecule for the treatment of multiple types of refractory/resistant solid cancers
Development Phase of Primary Product